background: Anti-Müllerian hormone (AMH) has been implicated in the pathogenesis of polycystic ovary syndrome (PCOS). The aim of this study was to measure circulating AMH before laparoscopic ovarian diathermy (LOD) to evaluate its prognostic value for an ovulatory response and to investigate AMH changes after LOD to further explore the effects of LOD.
Introduction
Anti-Müllerian hormone (AMH) is a dimeric glycoprotein, which is a member of the transforming growth factor family. In the female, AMH is secreted exclusively by granulosa cells of primary, pre-antral and small antral follicles (4 -6 mm) (Weenen et al., 2004) . Its secretion gradually diminishes in the subsequent stages of follicle development and is practically undetectable in follicles .8 mm (Weenen et al., 2004) . Serum AMH concentrations have been correlated with the number of small follicles and hence ovarian reserve. The size of the pool of small follicles remains relatively constant during the menstrual cycle and consequently circulating AMH concentrations show minimal fluctuation throughout the menstrual cycle. AMH gradually falls with advancing age owing to a depletion of the number of follicles as menopause approaches (Cook et al., 2000) .
Animal studies have shown AMH to have an inhibitory effect on primordial follicle recruitment, thereby preventing their rapid depletion (Durlinger et al., 1999) . AMH has also been shown to lower the sensitivity of follicles to circulating FSH (Durlinger et al., 2001) , an effect which is important for normal folliculogenesis. During follicular growth, as one follicle reaches a certain size (8 mm), its AMH expression decreases resulting in an increased sensitivity of that follicle to circulating FSH, thus allowing it to continue growth with low levels of FSH until ovulation (Weenen et al., 2004; Visser et al., 2006) .
Previous studies have shown women with polycystic ovary syndrome (PCOS) to have a 2-to 3-fold increase in serum AMH concentration, which corresponds to the 2-to 3-fold increase in the number of small (2 -5 mm) follicles seen in PCOS (Pigny et al., 2003; Laven et al., 2004) . This increase in AMH has been implicated in the pathogenesis of PCOS. It has been hypothesized that the high serum AMH levels in PCOS lower the follicle sensitivity to circulating FSH, thus preventing follicle selection and resulting in follicle arrest at the small antral phase, with failure of dominance. AMH also inhibits aromatase activity resulting in reduction of follicular production of estradiol (E 2 ) (di Clemente et al., 1994) . The resulting low levels of E 2 may also contribute to the failure of follicle selection.
Laparoscopic ovarian diathermy (LOD) is widely used to induce ovulation in anovular patients with PCOS. However, 30% of women with PCOS fail to respond to LOD and the exact cause of LOD failure in some patients remains uncertain. Identifying factors that determine the response of women with PCOS to LOD will help in selecting patients who are likely to benefit from this treatment, thus avoiding fruitless treatment and improving success rates. In a previous study, we have reported on factors affecting the success of LOD (Amer et al., 2004) . However, the prognostic value of AMH in women undergoing LOD has not previously been investigated. AMH has been found to correlate with ovarian responsiveness to ovulation induction with clomiphene citrate (El-Halawaty et al., 2007) and to FSH ovarian hyperstimulation for IVF treatment (Seifer et al., 2002; van Rooij et al., 2002; Kwee et al., 2008; Nardo et al., 2008) . We therefore hypothesized that the circulating level of AMH could be a useful predictor of response to LOD. The consistency of the serum levels of AMH throughout the entire menstrual cycle, with very little inter-cycle variability, makes it an attractive marker of response to treatment.
The mechanism of action of LOD is largely unexplained. In particular, it is not known whether LOD exerts its action through a direct effect on the ovary or through a systemic endocrine mechanism. AMH is not regulated by gonadotrophins and acts as an autocrine/paracrine, rather than a systemic, factor and thus is not part of a negative feedback loop involving gonadotrophins (Fanchin et al., 2003) . A change in the concentration of AMH in the circulation as a result of LOD may indicate that LOD acts locally to reduce intra-ovarian AMH secretion, thereby facilitating resumption of the intra-ovarian processes of follicle selection and progression to dominance and ovulation. The impact of LOD on serum AMH concentration has not been previously investigated.
The aim of this study was to evaluate the prognostic value of pretreatment plasma AMH level on the success rates of LOD. A second objective was to measure the post-operative changes of circulating AMH concentrations to see whether this could explain the mechanism of action of LOD.
Materials and Methods
This prospective study was conducted in a tertiary referral Fertility Centre. The study included 47 anovulatory women with PCOS who participated in an RCT carried out between March 2002 and March 2006 comparing LOD versus clomiphene citrate as a first-line method of ovulation induction (Amer et al., 2009) . Diagnostic criteria for PCOS included at least two of the following three features: clinical (oligo/amenorrhoea and/or hyperandrogenaemia), biochemical [LH !10 IU/l, LH/FSH ratio !2, testosterone .2.6 nmol/l or free androgen index (FAI) .5] and sonographic features (polycystic ovaries). Twenty-nine women had LOD and 18 received clomiphene citrate in incremental doses (50-150 mg). Blood samples were collected before and 1 week after LOD to measure plasma concentrations of AMH, LH, FSH, testosterone and sex hormonebinding globulin (SHBG) . Further blood samples were collected 3 and 6 months after LOD for the measurement of AMH. In women receiving clomiphene citrate, AMH was measured before treatment, on cycle Day 2 of the following menstrual cycle, and at 3-and 6-month follow-up.
LOD was carried out using a monopolar electrocautery needle. Four punctures were made per ovary at a power setting of 30 W applied for 5 s per puncture. Clomiphene citrate was given in incremental doses (50-150 mg) on Days 2 -6 of a menstrual cycle for up to six cycles. Ovulation was monitored for both treatments by measuring the serum concentration of progesterone on Day 21 of the menstrual cycle. If the patient did not ovulate after LOD, clomiphene citrate would be started 6 -8 weeks after surgery.
Plasma samples were assayed for AMH in duplicate using a commercial enzyme-linked immunosorbent assay kit (Immunotech, Beckman -Coulter UK Ltd, High Wycombe, Buckinghamshire, UK) according to the manufacturer's protocol. The sensitivity of the assay was 0.24 ng/ml. The intraand inter-assay variabilities were ,5% and 8%, respectively.
Assays for LH, FSH, testosterone and SHBG have previously been described (Li et al., 2000) . Assays for LH and FSH were performed by automated microparticle enzyme-immunoassay (Abbott Axsym analyser, Abbott Diagnostics). Assays for SHBG were performed by automated chemiluminescent immunoassay (Immulite analyser, Diagnostic Products Corporation). The assay used for testosterone was coated tube radioimmunoassay (Coat-A-Count, Diagnostic Products Corporation). The intra-and inter-assay coefficients of variation, respectively, were: LH, 4.5%, 10.4%; FSH 5.9%, 8.0%; testosterone 7.5%, 8.0%; SHBG 6.8%, 9.4%.
Statistical analysis
Data were entered into the Statistical Package for Social Sciences (SPSS) version 14. Plasma AMH values did not follow a normal distribution and were therefore compared using non-parametric statistical tests (MannWhitney U-test and Wilcoxon signed-ranks test). Comparisons of categorical data were carried out using x 2 and odds ratio with 95% confidence interval (OR, 95% CI). Receiver-operating characteristic (ROC) curve analysis was used to evaluate the prognostic value of plasma AMH levels. Multiple logistic regression analysis for categorical data was used to determine the independent predictors of success of LOD. Backward stepwise elimination was used for the multivariate logistic analysis of prediction of patients ovulating after LOD. A value of P . 0.10 was used as a cut-off level for exclusion of non-significant individual parameters from the prognostic model. The Cox and Snell square measure of goodness of fit was used to check for lack of fit of the final model. A P-value ,0.05 was considered statistically significant.
Results Table I shows the baseline characteristics of the 47 women with anovulatory PCOS included in this study and no significant differences were found between treatment groups. The pretreatment median (range) plasma concentration of AMH in the overall group of patients was 5.7 (1.0-21.0), which is higher than the previously reported values for the general population (2.9 + 1.6 ng/ml) (Pigny et al., 2003) . In women undergoing LOD, the median plasma concentration of AMH was 6.1 (1.0-21.0) ng/ml, which was not different (P ¼ 0.86) from that [5.7 (1.3-9.5) ng/ml] of women receiving clomiphene citrate (Table II) . Women who ovulated in response to LOD (responders) had a significantly (P ¼ 0.032) lower pre-operative AMH compared with the nonresponders (Table III) . Using ROC curve analysis, AMH was found to be a useful predictor of no ovulation after LOD, with an area under the curve (AUC) of .804 (P ¼ 0.025) (Fig. 1a) . Using a cut-off of 7.7 ng/ml, AMH had a sensitivity of 78% and a specificity of 76% in the prediction of no ovulation after LOD (Fig. 1a) . Women with AMH !7.7 ng/ml showed a significantly (P ¼ 0.036, OR 0.08, 95% CI 0.01-0.89) lower ovulation rate (60%) than that (95%) of women with AMH ,7.7 ng/ml (Table IV) . AMH was less useful in predicting no pregnancy with an AUC of 0.694 (Fig. 1b) . ROC curves revealed AMH to be less useful in predicting the outcome of clomiphene citrate treatment ( Fig. 1c and d) . Women with plasma AMH concentrations of !7.7 ng/ml were less likely to ovulate/conceive during clomiphene citrate treatment compared with those with AMH ,7.7 ng/ml, although the difference did not reach significance (Table IV) . In the overall group of patients (n ¼ 47), receiving clomiphene citrate or undergoing LOD, levels of AMH of !7.7 ng/ml were associated with significantly (P ¼ 0.004) lower chances of ovulation after treatment (Table IV) .
Spearman's rank correlation revealed significant positive correlations between AMH and both ovarian volume (r ¼ 0.425, P ¼ 0.006) and serum testosterone concentrations (r ¼ 0.448, P ¼ 0.002) (Fig. 2) . No significant correlation was found between plasma AMH and age, BMI, FAI, LH or FSH (Table V) BMI and age showed AMH to be the most important factor in determining ovulation after LOD. The final logistic regression model had an R 2 (Cox and Snell) of 0.295.
Following LOD, the median plasma AMH level significantly (P ¼ 0.003) decreased to 4.6 (range 0.3 -15.1) ng/ml and remained low at 3-and 6-month follow-up (Table II) . Further analysis revealed that the significant reduction of AMH had occurred only in women who ovulated in response to LOD (P ¼ 0.002, Table III ). In women receiving clomiphene citrate, the post-treatment levels of AMH [4.8 (2.7 -9.2) ng/ml] were not different (P ¼ 0.099) from the pretreatment level [5.7 (1.3 -9.5) ng/ml] (Table II) . Plasma hormone levels before and after LOD are presented in Table III . The pre-and post-LOD results are compared between the responders versus the non-responders. LOD responders had a significantly (P ¼ 0.016) Anti-Müllerian hormone and polycystic ovary syndrome lower pretreatment FAI [4.9 (1.8 -18.6)] compared with that [7.3 (6.3 -21.8 )] of the non-responders. No other significant differences in hormone levels were observed between the responders and the non-responders. A significant reduction of FAI following LOD was observed in the overall group of women as well as the nonresponders. LOD responders showed a small but significant (P ¼ 0.048) post-LOD fall of plasma testosterone concentration. No other hormonal changes were observed after LOD (Table III) .
Discussion
In this study, we have for the first time evaluated the prognostic value of plasma AMH for ovulation in women with PCOS undergoing LOD.
Plasma AMH concentration was found to be a potentially useful predictor of the outcome of LOD. We have also identified a cut-off level of AMH (7.7 ng/ml), above which the chances of ovulation seem to be significantly reduced. Failure of LOD in women with relatively high levels of AMH may be due to severity of the PCOS condition in these women. It is possible that the extent of follicle destruction by LOD in these women was not enough to reduce intra-ovarian AMH to a level consistent with resumption of ovulation. Future studies should evaluate whether increasing the number of punctures, or the energy per puncture, in these women could improve the response to LOD. We suggest that women who are candidates for undergoing LOD may benefit from measurement of serum AMH concentration to determine their likelihood of response. Patients found to have high serum AMH (!7.7 ng/ml) could be warned of the lower chances of success of the procedure. It remains to be seen whether high serum AMH has a similar effect on the chances of success of other methods of ovulation induction.
We have also found a positive correlation between AMH and ovarian volume. This is not surprising as ovarian volume is a reflection of the number of small antral follicles present in PCOS, which are the only source of AMH. There was also a positive correlation between AMH and circulating androgens. This is in agreement with previous studies by Pigny et al. (2003) and Eldar-Geva et al. (2005) . Pigny et al. (2003) also showed that this correlation is specific to PCOS because it was not observed in a control group of women without PCOS. This positive association between testosterone and AMH could be explained by the stimulatory effect of androgens on primordial follicular growth and granulosa cell proliferation, which in turn could increase AMH secretion (Vendola et al., 1998) . Another possible explanation is the inhibitory effect of AMH on aromatase activity, resulting in an increase in androgens. There has been no evidence to suggest a direct stimulatory effect of testosterone on AMH production by the granulosa cells (Pigny et al., 2003) . As AMH, ovarian volume and testosterone levels are closely related, we have used multiple logistic regression analysis to determine which of these factors is an independent predictor of ovulation. In that analysis, we have also included FAI and BMI, which we have previously shown to affect the probability of ovulation and pregnancy after LOD (Amer et al., 2004) . The analysis has clearly shown that AMH is the more important factor.
Several previous studies on ovarian reserve have shown low AMH levels to be associated with poor ovarian responsiveness to ovarian hyperstimulation in IVF programmes in women without PCOS (Seifer et al., 2002; van Rooij et al., 2002; Kwee et al., 2008; Nardo et al., 2008) . Taking this finding together with those in our study into consideration, it is possible to hypothesize that normal levels of AMH are necessary to achieve optimal ovarian responsiveness to ovulation induction. Both low and high levels of AMH seem to be detrimental to ovarian responsiveness to stimulation.
We have also evaluated the changes in circulating AMH concentrations after LOD. The data clearly showed a 25% reduction in plasma AMH in women undergoing LOD. This fall, which was significant, was only seen in women who ovulated after LOD. This reduction of AMH could be the result of destruction of some small follicles (which are the only source of AMH) during LOD. If this is true, it could be hypothesized that the fall in AMH resulting from LOD could lead to an increase in follicular responsiveness to circulating FSH, thus allowing further growth and selection of a dominant follicle. Alternatively, the post-operative reduction of AMH could be the result of atresia of several small follicles as part of normal follicular development leading to ovulation. If this is true, then the observed fall in AMH could be the result, rather than the cause, of ovulation after LOD. The hypothesis that the reduction of AMH is the cause of ovulation is supported by the finding that the FSH levels did not increase after LOD, suggesting that ovulation was a result of increased sensitivity of the follicles to FSH. This finding is consistent with our previous study, which showed no change in FSH levels after LOD (Amer et al., 2002) . However, this hypothesis is only speculative and cannot be confirmed by data from the present study. On the other hand, the fact that a similar trend of reduction of AMH (15%) was observed after clomiphene citrate treatment (although not significant, possibly owing to the small sample size) supports the hypothesis that the reduction of AMH after LOD and clomiphene citrate is the result rather than the cause of ovulation.
The reduction of testosterone levels and FAI observed in this study is consistent with several previous reports (Armar et al., 1990; Amer et al., 2002) . Also consistent with previous publications is the trend towards lowering LH levels observed after LOD in the responders only, although this did not reach significance (possibly a result of type II error). It is surprising to see that the reduction of FAI occurred in the non-responders, but not the responders. This fall could be explained by the 'regression to the mean phenomenon', which is likely to occur in this study due to the small number (n ¼ 5) of the non-responders.
In conclusion, measurement of serum AMH concentration before treatment may be a useful tool in predicting the outcome of LOD and clomiphene citrate administration. This could help in patient selection for treatment and may also help with counselling PCOS patients concerning the expected success of ovulation induction. Further studies are needed to investigate whether the post-operative reduction of AMH is the cause or the result of ovulation following LOD.
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